Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
AKT1 positive Perifosine ovarian clear cell carcinoma predicted - sensitive detail...
AKT1 positive Cisplatin + Perifosine ovarian clear cell carcinoma predicted - sensitive detail...
Unknown unknown GDC-0980 ovarian clear cell carcinoma not applicable detail...
ARID1A mutant Dasatinib ovarian clear cell carcinoma sensitive detail...
ARID1A mutant VE-821 ovarian clear cell carcinoma sensitive detail...
ARID1A mutant Berzosertib ovarian clear cell carcinoma sensitive detail...
ARID1A loss JQ1 ovarian clear cell carcinoma predicted - sensitive detail...
ARID1A dec exp Molibresib ovarian clear cell carcinoma predicted - sensitive detail...
ARID1A Q1148* JQ1 ovarian clear cell carcinoma predicted - sensitive detail...
Unknown unknown ENMD-2076 ovarian clear cell carcinoma no benefit detail...
ARID1A negative ENMD-2076 ovarian clear cell carcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02446600 Phase III Cediranib + Olaparib Olaparib Carboplatin + Gemcitabine + Paclitaxel + Pegylated liposomal-doxorubicin Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting
NCT02759588 Phase Ib/II GL-ONC1 GL-ONC1 Oncolytic Immunotherapy in Patients With Recurrent Ovarian Cancer Recruiting
NCT02879162 Phase II Durvalumab + Tremelimumab Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours Active, not recruiting
NCT02889900 Phase II Cediranib + Olaparib Efficacy and Safety Study of Cediranib in Combination With Olaparib in Patients With Recurrent Platinum-Resistant Ovarian Cancer (CONCERTO) Active, not recruiting
NCT02900651 Phase Ib/II MAK683 Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies Recruiting
NCT03134638 Phase I Carboplatin + SY-1365 SY-1365 Fulvestrant + SY-1365 A Study of SY-1365 in Adult Patients With Advanced Solid Tumors Active, not recruiting
NCT03348631 Phase II Tazemetostat Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer Suspended
NCT03355976 Phase II Ipilimumab + Nivolumab Nivolumab BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell Carcinomas Recruiting
NCT03602586 Phase II Epacadostat + Pembrolizumab Pembrolizumab and Epacadostat in Treating Participants With Recurrent, Persistent, or Progressive Ovarian Clear Cell Carcinoma Suspended
NCT03737643 Phase III Bevacizumab + Carboplatin + Paclitaxel Bevacizumab + Carboplatin + Durvalumab + Paclitaxel Bevacizumab + Durvalumab + Olaparib Olaparib Bevacizumab + Durvalumab Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. (DUO-O) Recruiting
NCT03840200 Phase Ib/II Ipatasertib + Rucaparib A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. Recruiting
NCT03955471 Phase II Dostarlimab + Niraparib A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and TSR-042 in Patients With Platinum Resistant Ovarian Cancer (MOONSTONE) Recruiting
NCT04034927 Phase II Olaparib Olaparib + Tremelimumab Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer Recruiting